Amylin, Takeda discontinue development of obesity treatment

Earlier on Thursday, Takeda Pharmaceutical Co. Ltd and Amylin Pharmaceuticals Inc. announced the discontinuation of the development of their combination obesity therapy, pramlintide/metreleptin.

The companies clarified that a commercial assessment has led to this decision. Christian Weyer, Senior vice president of research at Amylin said that they expect to develop a similar treatment with “less frequent dosing” in the future.
Since both companies have called off the development of their obesity treatment, neither one anticipates amending their latest fiscal 2011 guidance.